[Therapeutic drug monitoring: clinical practice]

Rev Med Suisse. 2008 Jul 16;4(165):1649-50, 1652-60.
[Article in French]

Abstract

When requesting a blood level measurement in the context of "Therapeutic drug monitoring" (TDM), numerous aspects have to be considered in the pre-analytical and analytical area, as in the integration of associated clinical data. This review presents therapeutic classes for which a clinical benefit of TDM is established or suggested, at least in some settings. For each class of drugs, the main pharmacokinetic, pre-analytical, analytical and clinical aspects are evaluated in the scope of such a monitoring. Each step of the TDM process is important and none should be neglected. Additional clinical trials are however warranted to better establish the exact conditions of use for such a monitoring.

Publication types

  • English Abstract

MeSH terms

  • Anti-Bacterial Agents / blood
  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Retroviral Agents / blood
  • Anti-Retroviral Agents / pharmacokinetics
  • Anticonvulsants / blood
  • Anticonvulsants / pharmacokinetics
  • Antineoplastic Agents / blood
  • Antineoplastic Agents / pharmacokinetics
  • Antiparasitic Agents / blood
  • Antiparasitic Agents / pharmacokinetics
  • Antitubercular Agents / blood
  • Antitubercular Agents / pharmacokinetics
  • Cardiovascular Agents / blood
  • Cardiovascular Agents / pharmacokinetics
  • Dose-Response Relationship, Drug
  • Drug Monitoring / methods*
  • Drug Monitoring / standards*
  • Evidence-Based Medicine
  • Humans
  • Immunosuppressive Agents / blood
  • Immunosuppressive Agents / pharmacokinetics
  • Product Surveillance, Postmarketing
  • Psychotropic Drugs / blood
  • Psychotropic Drugs / pharmacokinetics

Substances

  • Anti-Bacterial Agents
  • Anti-Retroviral Agents
  • Anticonvulsants
  • Antineoplastic Agents
  • Antiparasitic Agents
  • Antitubercular Agents
  • Cardiovascular Agents
  • Immunosuppressive Agents
  • Psychotropic Drugs